Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort
In this real-world cohort, treatment with tezepelumab for a median of 46 weeks was associated with improved asthma control, reductions in exacerbations, mOCS and inhaled corticosteroid doses, and a low symptom burden. These findings were consistent in biologic-experienced or low-eosinophil patients.
Authors
- Yaniv Dotan (ORCID: https://orcid.org/0000-0003-2421-4479)
- Amir Bar‐Shai (ORCID: https://orcid.org/0000-0001-9364-6887)
- Eviatar Naamany (ORCID: https://orcid.org/0000-0001-8909-9657)
- Mordechai Reuven Kramer (ORCID: https://orcid.org/0000-0003-2376-2393)
- Aviv Kupershmidt (ORCID: https://orcid.org/0000-0003-4224-4807)
- Jasmin Khateeb (ORCID: https://orcid.org/0000-0002-4575-2199)
- Ophir Freund (ORCID: https://orcid.org/0000-0002-7272-5284)
- Dror Rosengarten (ORCID: https://orcid.org/0000-0003-1754-5878)
- Ori Wand (ORCID: https://orcid.org/0000-0002-7702-2967)
- Anna Breslavsky (ORCID: https://orcid.org/0009-0007-3885-5505)
- Reem Mhameed
- Gal Elkayam
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Rabin Medical Center (IL)
- Rambam Health Care Campus (IL)
- Barzilai Medical Center (IL)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1183/23120541.00314-2025
- Citations
- 6
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.99